Alto Neuroscience, Inc. (NYSE:ANRO – Get Free Report) saw some unusual options trading activity on Wednesday. Investors purchased 2,129 call options on the stock. This is an increase of 21% compared to the typical daily volume of 1,755 call options.
Alto Neuroscience Price Performance
Shares of NYSE:ANRO opened at $4.36 on Thursday. Alto Neuroscience has a 1 year low of $4.26 and a 1 year high of $24.00. The firm has a fifty day moving average price of $12.22 and a 200 day moving average price of $12.48. The company has a current ratio of 19.85, a quick ratio of 19.85 and a debt-to-equity ratio of 0.04.
Alto Neuroscience (NYSE:ANRO – Get Free Report) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.07. On average, equities analysts expect that Alto Neuroscience will post -2.63 earnings per share for the current fiscal year.
Analyst Ratings Changes
View Our Latest Analysis on Alto Neuroscience
Institutional Investors Weigh In On Alto Neuroscience
A number of hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. bought a new stake in Alto Neuroscience during the first quarter valued at about $21,267,000. Price T Rowe Associates Inc. MD bought a new stake in Alto Neuroscience during the first quarter valued at about $9,788,000. Vanguard Group Inc. bought a new stake in Alto Neuroscience during the first quarter valued at about $8,233,000. Jennison Associates LLC bought a new stake in Alto Neuroscience during the first quarter valued at about $7,039,000. Finally, Artal Group S.A. bought a new stake in shares of Alto Neuroscience in the first quarter valued at about $5,372,000.
About Alto Neuroscience
Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.
Featured Articles
- Five stocks we like better than Alto Neuroscience
- Stock Market Upgrades: What Are They?
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Alto Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alto Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.